Drug General Information (ID: DDIV1W08S6)
Drug Name			Levacetylmethadol		Drug Info		Panitumumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Analgesics				Antineoplastics

Mechanism of Levacetylmethadol-Panitumumab Interaction (Severity Level: Major)
Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Drug Name		Levacetylmethadol				Panitumumab
Mechanism		Prolong QT interval				Hypomagnesemia
Key Mechanism Factor 1
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Levacetylmethadol and Panitumumab

Recommended Action
Management		Caution is advised if levomethadyl acetate must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with levomethadyl acetate. A 12-lead ECG should be performed before initiating therapy, 12 to 14 days after initiating therapy, and periodically thereafter. Patients should be advised to immediately seek medical attention if they experience palpitations, dizziness, lightheadedness, fainting, or seizures.

References
1	Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
2	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
3	Product Information. Xatral (alfuzosin). Sanofi-Synthelabo Canada Inc, Markham, ON.